KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2016 - 2025)

Rigel Pharmaceuticals has reported Income from Continuing Operations over the past 16 years, most recently at 268065000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 1769.22% year-over-year to 268065000.0; the TTM value through Dec 2025 reached 367024000.0, up 1999.08%, while the annual FY2025 figure was 367024000.0, 1999.08% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 268065000.0 at Rigel Pharmaceuticals, up from 27900000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 268065000.0 in Q4 2025 and troughed at 27445000.0 in Q1 2022.
  • A 5-year average of 14146500.0 and a median of 3361000.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 169.48% in 2022 and later soared 5887.67% in 2025.
  • Year by year, Income from Continuing Operations stood at 22606000.0 in 2021, then skyrocketed by 106.2% to 1401000.0 in 2022, then crashed by 47.39% to 737000.0 in 2023, then surged by 1845.86% to 14341000.0 in 2024, then skyrocketed by 1769.22% to 268065000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RIGL at 268065000.0 in Q4 2025, 27900000.0 in Q3 2025, and 59613000.0 in Q2 2025.